Why Kidney Drug Development Suddenly Became Valuable: From a BD Desert to Priority Asset in Big Pharma Portfolios
Date: 2026-8-27
**The Convergence of Niche Disease Asset Trading and Platform Strategy Logic**
**Abstract**
Over the past five years, kidney M&A has evolved from an edge track into a core strategic priority for major pharma: Vertex's $4.9 billion, Novartis's $3.5 billion, and Biogen's $5.6 billion acquisitions have landed in succession.
This is no coincidence. Rather, three developments have matured simultaneously: a replicable regulatory pathway has emerged for IgA nephropathy, surrogate endpoints have reduced development risk, and SGLT2/GLP-1 inhibitors have pulled CKD into the broader cardiorenal-metabolic strategic framework. Kidneys are no longer a niche chronic-disease segment — they are becoming a core battlefield where high-premium niche-disease transactions and large-platform strategy deployments converge.
**① Three Years Ago vs. Today — A Changed Reaction to the Same Quote**
Three years ago, if you told a large-pharma BD head, "I have an IgA nephropathy program," the likely response was polite interest at best. Today, the same sentence could directly trigger a bidding war.
Behind this shift is not simply "kidney diseases have suddenly become important." Rather, a more complex set of mechanisms is operating in concert: the regulatory path has sharpened, buyer capital pressures have intensified, and platform logic has begun to accommodate kidneys.
Flipping through M&A deal tables conveys the real weight of this inflection point far better than attending medical conferences ever could.
**② What's Really Being Reassessed Is Not Disease Burden but "Verifiability"**
This wave of kidney-sector warming is more accurately described with a single word: "verifiability" has returned.
Kidney diseases were not previously valueless — rather, they occupied an uncomfortable space because the field is not capital-friendly. Marked disease heterogeneity, slow endpoint progression, and lengthy trial timelines combined to make these programs read more like a scientific story that makes a BD head frown than a formal asset that can be slotted into an investment model, an M&A framework, or a franchise plan.
That calculus is now shifting. The macro backdrop is that major pharma companies are themselves reallocating capital. IQVIA noted in early 2026 that the industry still holds approximately $1.3 trillion in transaction capacity, while facing roughly $230 billion in revenue shortfall pressure by 2030. Against that backdrop, capital won't simply chase the hottest narrative; it will flow more actively toward areas that combine unmet need with growing regulatory and commercial predictability. Kidney diseases are one such area.
**③ IgA Nephropathy: The Most Visible Window in This Wave of Kidney Deals**
If we look only at the most-watched recent transactions, IgA nephropathy (IgAN) is unquestionably the most prominent window into the current wave of kidney-sector BD enthusiasm.
In 2024, Vertex announced the acquisition of Alpine Immune Sciences for approximately $4.9 billion. The core asset, povetacicept, targets the dual BAFF/APRIL pathway, and Vertex framed the deal in public materials not as a simple "pipeline fill-in" but as an important platform puzzle piece capable of covering IgAN and other immune-mediated kidney diseases.
Earlier, in 2023, Novartis announced its acquisition of Chinook for a $3.2 billion upfront cash payment plus milestone payments, bringing total deal value to approximately $3.5 billion. The two core assets — atrasentan and zigakibart — both represented high-value late-stage programs centered on IgAN.
Biogen's trajectory is equally illustrative. In 2024, it acquired HI-Bio for an $1.15 billion upfront payment to secure felzartamab, formally entering nephrology. By March 2026, it announced a $5.6 billion acquisition of Apellis plus assumption of liabilities. The first transaction acquired clinical assets and a market-entry ticket; the second clearly carried franchise-expansion and commercial-capability-complement objectives.
Viewed together, the logic is already clear: IgAN is no longer just a "small and niche" rare-kidney-disease story. It has become a high-quality entry point for major pharma to either break into or deepen their renal franchise.
**④ Why IgAN Heated Up First: Because the Regulatory Pathway Has Gotten Substantially Clearer**
**Core question: The shortage has never been unmet need — it's been predictability.**
Many kidney diseases have historically been difficult to develop not because of a lack of biological rationale, but because regulatory "success criteria" lacked operational clarity. Long waiting periods and hard clinical outcomes meant discounted project valuations, extended development timelines, and higher M&A friction. For capital, these tracks often have ample unmet need but lack predictability.
One core reason IgAN has warmed so quickly in recent years is that the regulatory status of surrogate endpoints has become significantly clearer.
- **Tarpeyo** first received accelerated approval in 2021 based on proteinuria reduction and then full approval in December 2023, with the label expanded to "reduce risk of kidney function loss." The significance of this case extends well beyond the product's success — it demonstrated a pathway: early surrogate endpoints can serve as a genuine bridge to confirmed clinical benefit in kidney diseases.
- **Vanrafia** received FDA accelerated approval in April 2025 to reduce proteinuria in adult patients with IgAN.
- **Voyxact** then received FDA accelerated approval in November 2025, similarly anchored on proteinuria reduction.
Several products advancing along comparable logic carries far greater meaning for BD than any single approval event alone — once a track develops a replicable regulatory pathway, buyers' assessment of project value undergoes a structural shift.
At a deeper level, the regulatory discussion around eGFR slope in CKD randomized controlled trials has also matured significantly. EMA's 2023 qualification opinion on eGFR slope discussed its use as a confirmatory surrogate endpoint in CKD clinical trials. Although specific determinations are still needed depending on disease and development context, the overall direction is very clear: kidney development is no longer confined to the latest, most protracted hard endpoints. For capital markets, this kind of directional clarity is itself an important prerequisite for increased deal flow.
**⑤ But Focusing Only on IgAN Would Still Understate the Kidney Track**
**CKD: From an isolated nephrology problem to the core of an integrated CVRM strategy.**
If IgAN represents the most "visible" hotspot in this wave of kidney deals, then CKD represents the larger base-market opportunity and the stronger platform value.
The KDIGO 2024 CKD guideline itself reflects an important fact: CKD is increasingly not an isolated nephrology issue but a disease framework deeply coupled with diabetes, cardiovascular risk, metabolic management, and long-term complication control. In other words, CKD's commercial significance lies not only in nephrology per se but in its gradual penetration into the core of integrated cardiorenal-metabolic (CVRM) strategy.
This shift was first rewritten by SGLT2 inhibitors. In 2021, the FDA approved dapagliflozin to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adult patients with CKD. This approval was highly consequential because it moved CKD from a domain focused more on "risk management" and "end-of-disease support" into one where pharmacological intervention can modify disease course and improve hard outcomes. DAPA-CKD and subsequent EMPA-KIDNEY and other studies further consolidated this understanding.
Then GLP-1 agonists advanced CKD's strategic position a step further. The FLOW study showed that semaglutide reduces the risk of major renal outcomes and cardiovascular death in patients with type 2 diabetes and CKD; the FDA also approved a new Ozempic indication in January 2025 to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adult patients with type 2 diabetes and CKD. This means CKD is no longer merely a single-point success for SGLT2 inhibitors — it is becoming a long-term battleground where multiple mechanisms can continuously enter and where deep synergy with diabetes and cardiovascular franchises is achievable.
**One-sentence summary:** IgAN delivers "good deals"; CKD delivers "grand strategy." The former is more likely to produce high-premium niche-disease asset transactions; the latter is more likely to determine whether a major pharma company truly incorporates kidneys into its core strategic portfolio. The most sophisticated kidney strategies typically cover both niche breakthroughs and base-market expansion — they don't bet solely on IgAN, nor do they rest content with broadly defined CKD.
**⑥ Other Kidney Diseases Are Also Heating Up, but Under Different Logics**
Broadening the lens further, we find that kidney is not simply warming along two lines — IgAN and CKD. Other sub-specialty kidney diseases are also rapidly entering clearer competitive landscapes, each representing a distinct value logic.
**FSGS** is a typical example. In 2025, Amicus and Dimerix struck a U.S. exclusive license deal for DMX-200 with a $30 million upfront payment plus milestones. While such deal sizes may not match headline-making M&A, they signal an important different pattern: for rare kidney diseases, as long as a program is sufficiently late-stage and the development path is clear enough, even a regional-rights-type BD transaction can carry substantial strategic value without requiring a full-company acquisition.
**C3G** represents the continued deepening of complement-targeting assets in nephrology. In 2025, the FDA approved Fabhalta for adult C3G to reduce proteinuria, and later that year approved Empaveli for C3G or primary immune-complex MPGN in patients aged 12 and older, also to reduce proteinuria. For major pharma, the value of such complement assets lies not only in individual indications but in their ability to underpin broader renal-immune platforms. Biogen's acquisition of Apellis and Novartis's strengthening of its own complement footprint can both be understood through this logic.
**ADPKD** aligns more closely with the integration of "precision chronic disease" and long-term disease-modifying strategy. In 2025, Novartis announced the acquisition of Regulus, whose core asset farabursen is a miR-17 inhibitor targeted at ADPKD. This reflects a different platform approach: beyond traditional kidney chronic diseases, buyers are also seeking assets with stronger genetic and precision-medicine attributes that offer opportunities to establish differentiated long-term positioning.
**APOL1-related kidney diseases** represent the kidney field's continued push toward "root-cause therapy." Vertex has advanced inaxaplin into subsequent pivotal studies for APOL1-mediated kidney disease and continues to update it as an important component of its renal pipeline. Compared to traditional strategies centered on inflammation or proteinuria control, these programs are closer to etiological intervention at the level of genetically driven subpopulations. They may not be the highest-volume M&A segment in the near term, but they are likely among the highest-valued asset classes for future platforms.
**⑦ What Large Pharma Actually Buys in Kidneys Today**
Looking at these transactions and assets together, we see that large pharma today is no longer buying "just a promising molecule" in the kidney space.
They are buying three things:
- **Late-stage assets partially de-risked by regulators** — programs with a clear mechanism, advancing through interpretable endpoints, and preferably already standing on a registration path. This explains why IgAN became a deal hotspot over the past few years.
- **Platform capabilities that can expand into multi-mechanism combinations** — today's renal landscape increasingly resembles oncology or immunology: single mechanisms matter, but what truly determines franchise ceiling is whether one can build complementary combinations — connections among complement, B-cell/plasma-cell, APRIL/BAFF, endothelin, genetic mechanisms, and the cardiorenal-metabolic base.
- **Commercial execution capability that can be absorbed by existing commercial systems** — kidneys were undervalued not only because R&D was difficult, but also because commercialization was immature. That is changing too. Biogen's explicit treatment of Apellis's renal commercial capability as a synergistic component signals that buyers are no longer satisfied with acquiring projects alone — they are beginning to buy organizational capability for entering the renal market.
**⑧ Closing: The Kidney Track Is No Longer Just "Worth Watching" — It's "Worth Allocating To"**
If one sentence could capture the change in kidney-sector BD today, it would be this: kidneys are no longer just a high-burden, low-transaction-efficiency niche track — they now simultaneously possess niche-disease transaction value and large-market platform value.
IgAN shows buyers how high-quality niche-disease assets are being repriced; CKD shows them how kidneys are entering the CVRM core strategic map; FSGS, C3G, ADPKD, and APOL1-related kidney diseases represent the longer-horizon growth directions of rare disease, complement platform, precision chronic disease, and root-cause therapy, respectively.
In other words, what makes the kidney field most interesting today is not the isolated breakout of any single disease — it's that the field for the first time presents a complete track morphology that can be layered, combined, and platformized.
This also means that the most attractive kidney assets going forward will likely be those that answer all three questions simultaneously:
- Is there a sufficiently clear biological rationale?
- Is the regulatory path becoming increasingly defined?
- Can it be slotted into a buyer's larger platform strategy?
Whoever builds their assets into that form earliest will be best positioned to seize the initiative in the next round of kidney-sector transactions.
**Abstract**
Over the past five years, kidney M&A has evolved from an edge track into a core strategic priority for major pharma: Vertex's $4.9 billion, Novartis's $3.5 billion, and Biogen's $5.6 billion acquisitions have landed in succession.
This is no coincidence. Rather, three developments have matured simultaneously: a replicable regulatory pathway has emerged for IgA nephropathy, surrogate endpoints have reduced development risk, and SGLT2/GLP-1 inhibitors have pulled CKD into the broader cardiorenal-metabolic strategic framework. Kidneys are no longer a niche chronic-disease segment — they are becoming a core battlefield where high-premium niche-disease transactions and large-platform strategy deployments converge.
**① Three Years Ago vs. Today — A Changed Reaction to the Same Quote**
Three years ago, if you told a large-pharma BD head, "I have an IgA nephropathy program," the likely response was polite interest at best. Today, the same sentence could directly trigger a bidding war.
Behind this shift is not simply "kidney diseases have suddenly become important." Rather, a more complex set of mechanisms is operating in concert: the regulatory path has sharpened, buyer capital pressures have intensified, and platform logic has begun to accommodate kidneys.
Flipping through M&A deal tables conveys the real weight of this inflection point far better than attending medical conferences ever could.
**② What's Really Being Reassessed Is Not Disease Burden but "Verifiability"**
This wave of kidney-sector warming is more accurately described with a single word: "verifiability" has returned.
Kidney diseases were not previously valueless — rather, they occupied an uncomfortable space because the field is not capital-friendly. Marked disease heterogeneity, slow endpoint progression, and lengthy trial timelines combined to make these programs read more like a scientific story that makes a BD head frown than a formal asset that can be slotted into an investment model, an M&A framework, or a franchise plan.
That calculus is now shifting. The macro backdrop is that major pharma companies are themselves reallocating capital. IQVIA noted in early 2026 that the industry still holds approximately $1.3 trillion in transaction capacity, while facing roughly $230 billion in revenue shortfall pressure by 2030. Against that backdrop, capital won't simply chase the hottest narrative; it will flow more actively toward areas that combine unmet need with growing regulatory and commercial predictability. Kidney diseases are one such area.
**③ IgA Nephropathy: The Most Visible Window in This Wave of Kidney Deals**
If we look only at the most-watched recent transactions, IgA nephropathy (IgAN) is unquestionably the most prominent window into the current wave of kidney-sector BD enthusiasm.
In 2024, Vertex announced the acquisition of Alpine Immune Sciences for approximately $4.9 billion. The core asset, povetacicept, targets the dual BAFF/APRIL pathway, and Vertex framed the deal in public materials not as a simple "pipeline fill-in" but as an important platform puzzle piece capable of covering IgAN and other immune-mediated kidney diseases.
Earlier, in 2023, Novartis announced its acquisition of Chinook for a $3.2 billion upfront cash payment plus milestone payments, bringing total deal value to approximately $3.5 billion. The two core assets — atrasentan and zigakibart — both represented high-value late-stage programs centered on IgAN.
Biogen's trajectory is equally illustrative. In 2024, it acquired HI-Bio for an $1.15 billion upfront payment to secure felzartamab, formally entering nephrology. By March 2026, it announced a $5.6 billion acquisition of Apellis plus assumption of liabilities. The first transaction acquired clinical assets and a market-entry ticket; the second clearly carried franchise-expansion and commercial-capability-complement objectives.
Viewed together, the logic is already clear: IgAN is no longer just a "small and niche" rare-kidney-disease story. It has become a high-quality entry point for major pharma to either break into or deepen their renal franchise.
**④ Why IgAN Heated Up First: Because the Regulatory Pathway Has Gotten Substantially Clearer**
**Core question: The shortage has never been unmet need — it's been predictability.**
Many kidney diseases have historically been difficult to develop not because of a lack of biological rationale, but because regulatory "success criteria" lacked operational clarity. Long waiting periods and hard clinical outcomes meant discounted project valuations, extended development timelines, and higher M&A friction. For capital, these tracks often have ample unmet need but lack predictability.
One core reason IgAN has warmed so quickly in recent years is that the regulatory status of surrogate endpoints has become significantly clearer.
- **Tarpeyo** first received accelerated approval in 2021 based on proteinuria reduction and then full approval in December 2023, with the label expanded to "reduce risk of kidney function loss." The significance of this case extends well beyond the product's success — it demonstrated a pathway: early surrogate endpoints can serve as a genuine bridge to confirmed clinical benefit in kidney diseases.
- **Vanrafia** received FDA accelerated approval in April 2025 to reduce proteinuria in adult patients with IgAN.
- **Voyxact** then received FDA accelerated approval in November 2025, similarly anchored on proteinuria reduction.
Several products advancing along comparable logic carries far greater meaning for BD than any single approval event alone — once a track develops a replicable regulatory pathway, buyers' assessment of project value undergoes a structural shift.
At a deeper level, the regulatory discussion around eGFR slope in CKD randomized controlled trials has also matured significantly. EMA's 2023 qualification opinion on eGFR slope discussed its use as a confirmatory surrogate endpoint in CKD clinical trials. Although specific determinations are still needed depending on disease and development context, the overall direction is very clear: kidney development is no longer confined to the latest, most protracted hard endpoints. For capital markets, this kind of directional clarity is itself an important prerequisite for increased deal flow.
**⑤ But Focusing Only on IgAN Would Still Understate the Kidney Track**
**CKD: From an isolated nephrology problem to the core of an integrated CVRM strategy.**
If IgAN represents the most "visible" hotspot in this wave of kidney deals, then CKD represents the larger base-market opportunity and the stronger platform value.
The KDIGO 2024 CKD guideline itself reflects an important fact: CKD is increasingly not an isolated nephrology issue but a disease framework deeply coupled with diabetes, cardiovascular risk, metabolic management, and long-term complication control. In other words, CKD's commercial significance lies not only in nephrology per se but in its gradual penetration into the core of integrated cardiorenal-metabolic (CVRM) strategy.
This shift was first rewritten by SGLT2 inhibitors. In 2021, the FDA approved dapagliflozin to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adult patients with CKD. This approval was highly consequential because it moved CKD from a domain focused more on "risk management" and "end-of-disease support" into one where pharmacological intervention can modify disease course and improve hard outcomes. DAPA-CKD and subsequent EMPA-KIDNEY and other studies further consolidated this understanding.
Then GLP-1 agonists advanced CKD's strategic position a step further. The FLOW study showed that semaglutide reduces the risk of major renal outcomes and cardiovascular death in patients with type 2 diabetes and CKD; the FDA also approved a new Ozempic indication in January 2025 to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adult patients with type 2 diabetes and CKD. This means CKD is no longer merely a single-point success for SGLT2 inhibitors — it is becoming a long-term battleground where multiple mechanisms can continuously enter and where deep synergy with diabetes and cardiovascular franchises is achievable.
**One-sentence summary:** IgAN delivers "good deals"; CKD delivers "grand strategy." The former is more likely to produce high-premium niche-disease asset transactions; the latter is more likely to determine whether a major pharma company truly incorporates kidneys into its core strategic portfolio. The most sophisticated kidney strategies typically cover both niche breakthroughs and base-market expansion — they don't bet solely on IgAN, nor do they rest content with broadly defined CKD.
**⑥ Other Kidney Diseases Are Also Heating Up, but Under Different Logics**
Broadening the lens further, we find that kidney is not simply warming along two lines — IgAN and CKD. Other sub-specialty kidney diseases are also rapidly entering clearer competitive landscapes, each representing a distinct value logic.
**FSGS** is a typical example. In 2025, Amicus and Dimerix struck a U.S. exclusive license deal for DMX-200 with a $30 million upfront payment plus milestones. While such deal sizes may not match headline-making M&A, they signal an important different pattern: for rare kidney diseases, as long as a program is sufficiently late-stage and the development path is clear enough, even a regional-rights-type BD transaction can carry substantial strategic value without requiring a full-company acquisition.
**C3G** represents the continued deepening of complement-targeting assets in nephrology. In 2025, the FDA approved Fabhalta for adult C3G to reduce proteinuria, and later that year approved Empaveli for C3G or primary immune-complex MPGN in patients aged 12 and older, also to reduce proteinuria. For major pharma, the value of such complement assets lies not only in individual indications but in their ability to underpin broader renal-immune platforms. Biogen's acquisition of Apellis and Novartis's strengthening of its own complement footprint can both be understood through this logic.
**ADPKD** aligns more closely with the integration of "precision chronic disease" and long-term disease-modifying strategy. In 2025, Novartis announced the acquisition of Regulus, whose core asset farabursen is a miR-17 inhibitor targeted at ADPKD. This reflects a different platform approach: beyond traditional kidney chronic diseases, buyers are also seeking assets with stronger genetic and precision-medicine attributes that offer opportunities to establish differentiated long-term positioning.
**APOL1-related kidney diseases** represent the kidney field's continued push toward "root-cause therapy." Vertex has advanced inaxaplin into subsequent pivotal studies for APOL1-mediated kidney disease and continues to update it as an important component of its renal pipeline. Compared to traditional strategies centered on inflammation or proteinuria control, these programs are closer to etiological intervention at the level of genetically driven subpopulations. They may not be the highest-volume M&A segment in the near term, but they are likely among the highest-valued asset classes for future platforms.
**⑦ What Large Pharma Actually Buys in Kidneys Today**
Looking at these transactions and assets together, we see that large pharma today is no longer buying "just a promising molecule" in the kidney space.
They are buying three things:
- **Late-stage assets partially de-risked by regulators** — programs with a clear mechanism, advancing through interpretable endpoints, and preferably already standing on a registration path. This explains why IgAN became a deal hotspot over the past few years.
- **Platform capabilities that can expand into multi-mechanism combinations** — today's renal landscape increasingly resembles oncology or immunology: single mechanisms matter, but what truly determines franchise ceiling is whether one can build complementary combinations — connections among complement, B-cell/plasma-cell, APRIL/BAFF, endothelin, genetic mechanisms, and the cardiorenal-metabolic base.
- **Commercial execution capability that can be absorbed by existing commercial systems** — kidneys were undervalued not only because R&D was difficult, but also because commercialization was immature. That is changing too. Biogen's explicit treatment of Apellis's renal commercial capability as a synergistic component signals that buyers are no longer satisfied with acquiring projects alone — they are beginning to buy organizational capability for entering the renal market.
**⑧ Closing: The Kidney Track Is No Longer Just "Worth Watching" — It's "Worth Allocating To"**
If one sentence could capture the change in kidney-sector BD today, it would be this: kidneys are no longer just a high-burden, low-transaction-efficiency niche track — they now simultaneously possess niche-disease transaction value and large-market platform value.
IgAN shows buyers how high-quality niche-disease assets are being repriced; CKD shows them how kidneys are entering the CVRM core strategic map; FSGS, C3G, ADPKD, and APOL1-related kidney diseases represent the longer-horizon growth directions of rare disease, complement platform, precision chronic disease, and root-cause therapy, respectively.
In other words, what makes the kidney field most interesting today is not the isolated breakout of any single disease — it's that the field for the first time presents a complete track morphology that can be layered, combined, and platformized.
This also means that the most attractive kidney assets going forward will likely be those that answer all three questions simultaneously:
- Is there a sufficiently clear biological rationale?
- Is the regulatory path becoming increasingly defined?
- Can it be slotted into a buyer's larger platform strategy?
Whoever builds their assets into that form earliest will be best positioned to seize the initiative in the next round of kidney-sector transactions.
